Free Trial

Mesa Laboratories Q3 2024 Earnings Report

Mesa Laboratories logo
$132.08 +0.68 (+0.52%)
(As of 12/20/2024 05:23 PM ET)

Mesa Laboratories EPS Results

Actual EPS
$1.46
Consensus EPS
$1.47
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Mesa Laboratories Revenue Results

Actual Revenue
$53.47 million
Expected Revenue
$54.90 million
Beat/Miss
Missed by -$1.43 million
YoY Revenue Growth
N/A

Mesa Laboratories Announcement Details

Quarter
Q3 2024
Time
N/A
2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisis (Ad)

Dan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.

Click here to see Dan's full warning to the public.

Mesa Laboratories Earnings Headlines

Mesa Labs price target lowered to $150 from $160 at Evercore ISI
Mesa Laboratories Reports Robust Q2 FY25 Results
This is the worst sign for the U.S. stock market in 50 years
The Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts now says this is just the beginning of a new crisis that could be worse than the COVID crash, the dot-com crash, and even the Great Depression. Introducing "The Dead Zone"
Mesa Labs Announces Second Quarter Results
MESA LABS DECLARES QUARTERLY DIVIDEND
See More Mesa Laboratories Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Mesa Laboratories? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mesa Laboratories and other key companies, straight to your email.

About Mesa Laboratories

Mesa Laboratories (NASDAQ:MLAB) develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. The Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. The Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems, offered under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.

View Mesa Laboratories Profile

More Earnings Resources from MarketBeat

Upcoming Earnings